$NGNE
Neurogene Inc.

2014 Q2 Form 10-Q Financial Statement

#000119312514195836 Filed on May 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.080M $740.0K $420.0K
YoY Change 191.89% 76.19%
% of Gross Profit
Research & Development $4.551M $1.880M $573.0K
YoY Change 264.93% 228.12%
% of Gross Profit
Depreciation & Amortization $71.94K $18.24K $14.79K
YoY Change 361.38% 23.35%
% of Gross Profit
Operating Expenses $5.632M $2.615M $996.8K
YoY Change 248.33% 162.33%
Operating Profit
YoY Change
Interest Expense $2.000K $454.0K $1.834K
YoY Change 13.06% 24654.63%
% of Operating Profit
Other Income/Expense, Net $208.0K -$1.613M -$13.44K
YoY Change -74.17% 11905.95%
Pretax Income -$5.424M -$4.228M -$1.010M
YoY Change 568.39% 318.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.424M -$4.228M -$1.010M
YoY Change 568.39% 318.5%
Net Earnings / Revenue
Basic Earnings Per Share -$1.28 -$8.48
Diluted Earnings Per Share -$507.5K -$1.28 -$8.48
COMMON SHARES
Basic Shares Outstanding 10.68M shares 3.148M shares 301.7K shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.90M $55.60M
YoY Change
Cash & Equivalents $17.90M $52.92M $19.02M
Short-Term Investments $18.00M $2.700M
Other Short-Term Assets $400.0K $500.0K
YoY Change
Inventory
Prepaid Expenses $424.2K $547.8K
Receivables $0.00 $100.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $36.34M $56.25M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $116.9K $67.38K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.50M
YoY Change
Other Assets $16.77K $135.3K
YoY Change
Total Long-Term Assets $16.62M $202.7K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $36.34M $56.25M
Total Long-Term Assets $16.62M $202.7K
Total Assets $52.96M $56.45M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.800M $1.200M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $2.846M $1.238M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $7.047K
YoY Change
Total Long-Term Liabilities $100.0K $7.047K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.846M $1.238M
Total Long-Term Liabilities $100.0K $7.047K
Total Liabilities $2.939M $1.352M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$75.04M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.02M -$65.39M
YoY Change
Total Liabilities & Shareholders Equity $52.96M $56.45M
YoY Change

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$5.424M -$4.228M -$1.010M
YoY Change 568.39% 318.5%
Depreciation, Depletion And Amortization $71.94K $18.24K $14.79K
YoY Change 361.38% 23.35%
Cash From Operating Activities -$2.810M -$3.800M -$900.0K
YoY Change 95.14% 322.22%
INVESTING ACTIVITIES
Capital Expenditures $64.61K $4.000K $4.696K
YoY Change 2446.75% -14.82%
Acquisitions
YoY Change
Other Investing Activities -$31.76M $0.00 $50.00K
YoY Change -28972.73% -100.0%
Cash From Investing Activities -$31.83M $0.00 $50.00K
YoY Change -31930.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -390.0K 45.72M 17.87M
YoY Change 333.33% 155.85%
NET CHANGE
Cash From Operating Activities -2.810M -3.800M -900.0K
Cash From Investing Activities -31.83M 0.000 50.00K
Cash From Financing Activities -390.0K 45.72M 17.87M
Net Change In Cash -35.03M 41.92M 17.02M
YoY Change 2349.65% 146.3%
FREE CASH FLOW
Cash From Operating Activities -$2.810M -$3.800M -$900.0K
Capital Expenditures $64.61K $4.000K $4.696K
Free Cash Flow -$2.875M -$3.804M -$904.7K
YoY Change 99.27% 320.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2014Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
11.00
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-68777919
CY2014Q1 aqxp Stock Shares Authorized Net
StockSharesAuthorizedNet
55000000 shares
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10675260 shares
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19017252
CY2014Q1 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
1.00 pure
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
124713456
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1237602
CY2014Q1 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7047
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
55097242
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1220695
CY2014Q1 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
CY2014Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
107597
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56449488
CY2014Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1797412
CY2014Q1 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
CY2014Q1 us-gaap Liabilities
Liabilities
1352246
CY2014Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16907
CY2014Q1 us-gaap Assets Current
AssetsCurrent
56246765
CY2014Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
66526
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135344
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
547812
CY2014Q1 us-gaap Assets
Assets
56449488
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52918327
CY2008 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
139758
CY2008 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
103518
CY2008 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
1008153
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7714198
CY2013Q4 aqxp Derivative Liabilities Noncurrent Redemption Option
DerivativeLiabilitiesNoncurrentRedemptionOption
800206
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-838306
CY2014Q1 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
47341278
CY2014Q1 us-gaap Short Term Investments
ShortTermInvestments
2714100
CY2014Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
69616225
CY2014Q1 us-gaap Cash
Cash
49538874
CY2014Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3379453
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67379
CY2014Q1 aqxp Unrecognized Share Based Compensation Expense
UnrecognizedShareBasedCompensationExpense
1485971
CY2013Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
2036489
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8560
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-65693708
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
73858722
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2350660
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
-11388
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
-31013
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
10708
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
-2425747
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
-8929597
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
-14105745
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-25113553
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-39314581
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-51101207
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000539
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2620105
CY2013Q4 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
250000
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
221320
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15649106
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1797412
CY2013Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2286489
CY2013Q4 us-gaap Liabilities
Liabilities
7484092
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19445
CY2013Q4 us-gaap Assets Current
AssetsCurrent
15296351
CY2013Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
27946
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
277290
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
63975
CY2013Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1377438
CY2013Q4 us-gaap Assets
Assets
15649106
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11006392
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
2820600
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
65693708
CY2013Q4 us-gaap Cash
Cash
7292116
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3714276
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
168702
CY2014Q1 aqxp Number Of Non Employee Directors
NumberOfNonEmployeeDirectors
4 Directors
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38237
CY2014Q1 aqxp Conversion Of Preferred Stock Into Common Stock
ConversionOfPreferredStockIntoCommonStock
77333952
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.052083 pure
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75465
CY2009 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
74743
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8529753
CY2010 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
8
CY2008 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
3
CY2009 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
3
CY2009 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
159611
CY2009 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
111673
CY2009 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
1301400
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4830000 shares
CY2014Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
5788726
CY2014Q1 aqxp Net Proceeds From Issuance Initial Public Offering
NetProceedsFromIssuanceInitialPublicOffering
47341274
CY2005 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19275
CY2005 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
350
CY2006 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-543052
CY2006 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
489451
CY2006 us-gaap Stock Issued During Period Value Issued For Noncash Considerations
StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
44834
CY2006 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50488
CY2007 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2008534
CY2007 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
10
CY2007 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
65024
CY2007 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
78255
CY2007 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
441162
CY2009 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3752070
CY2010 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
175467
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
109256
CY2010 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
2167601
CY2010 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
244251
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10507008
CY2011 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
7
CY2011 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
163483
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
118243
CY2011 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
3303200
CY2011 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
345587
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8729371
CY2013 us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
7
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
123074
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2500000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349321
CY2013 aqxp Discount On Issuance Of Warrants
DiscountOnIssuanceOfWarrants
226255
CY2013 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
5351459
CY2013 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
737925
CY2013 aqxp Payments Of Financing Costs Debt
PaymentsOfFinancingCostsDebt
12744
CY2008 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5459460
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
351322
CY2012 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
3860140
CY2012 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
394908
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12188
us-gaap Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
800
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0296 pure
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-179.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
398573 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-179.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M27D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
398573 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48602784
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.23
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-179.45
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
398573 shares
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-239484
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
626223
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51502587
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5398381
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
2820600
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54652993
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
134553
us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
107911
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71522489
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
255775
us-gaap Repayments Of Debt
RepaymentsOfDebt
100000
us-gaap Investment Income Interest
InvestmentIncomeInterest
365881
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
183629
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
66524
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2102193
us-gaap Interest Paid
InterestPaid
31719
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1431558
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-106501
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-622455
us-gaap Net Income Loss
NetIncomeLoss
-51502587
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
350
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549003
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
854211
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10241412
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
104882526
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
720863
us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
57835418
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1014667
us-gaap Share Based Compensation
ShareBasedCompensation
1409722
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.48
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
301745 shares
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5960985 shares
CY2013Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-17005
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10480
aqxp Share Issuance Expenditures Incurred But Not Yet Paid
ShareIssuanceExpendituresIncurredButNotYetPaid
390345
aqxp Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock
ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock
439227
aqxp Repayment Fee And Penalty
RepaymentFeeAndPenalty
100000
aqxp Reversal Of Income Tax Payable On Preferred Stock
ReversalOfIncomeTaxPayableOnPreferredStock
1897702
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3389372
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
19550
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
44834
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
52918327
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3361415
us-gaap Interest Expense
InterestExpense
590023
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
490176
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
191817
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
53130000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43789126
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
629410
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
333877
us-gaap Operating Expenses
OperatingExpenses
54030538
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3150406
aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
2395575
aqxp Incremental Common Shares Attributable To Common Stock Warrants
IncrementalCommonSharesAttributableToCommonStockWarrants
shares
aqxp Incremental Common Shares Attributable To Stock Options
IncrementalCommonSharesAttributableToStockOptions
shares
aqxp Amortization Of Discount On Preferred Stock
AmortizationOfDiscountOnPreferredStock
2395575
aqxp Special Voting Common Stock Issued Value
SpecialVotingCommonStockIssuedValue
44
aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
18566008
aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
1897702
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
99417
CY2014Q1 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
1132893
CY2014Q1 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
100291
CY2014Q1 aqxp Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock
ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock
1458478
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.48
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
301745 shares
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.48
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301745 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-896621
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.00
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1010267
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1010267
CY2013Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
29396
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2558530
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1446
CY2013Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
170
CY2013Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
132748
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13435
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1010267
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4696
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
37835
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
423865
CY2013Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
17867220
CY2013Q1 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
17999961
CY2013Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
44307
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
54674
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17016713
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
46114
CY2013Q1 us-gaap Interest Expense
InterestExpense
1834
CY2013Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50810
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
572967
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14785
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
996832
CY2013Q1 aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
25438
CY2013Q1 aqxp Incremental Common Shares Attributable To Common Stock Warrants
IncrementalCommonSharesAttributableToCommonStockWarrants
shares
CY2013Q1 aqxp Incremental Common Shares Attributable To Stock Options
IncrementalCommonSharesAttributableToStockOptions
shares
CY2013Q1 aqxp Amortization Of Discount On Preferred Stock
AmortizationOfDiscountOnPreferredStock
25438
CY2013Q1 aqxp Special Voting Common Stock Issued Value
SpecialVotingCommonStockIssuedValue
7
CY2013Q1 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
1157865
CY2013Q1 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
346091
CY2014Q1 dei Trading Symbol
TradingSymbol
AQXP
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
AQUINOX PHARMACEUTICALS, INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2007-05-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404644
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3148481 shares
CY2014Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effected a 1-for-19.2 reverse stock split
CY2014Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0152 pure
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.28
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.28
CY2014Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Nature of operations</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals Inc., (consolidated and combined the &#x201C;Company&#x201D;&#x2014;see Note&#xA0;2 Basis of presentation) are a clinical stage pharmaceutical company discovering and developing oral drug candidates to treat inflammation and cancer. The Company&#x2019;s primary focus is the development of anti-inflammatory product candidates targeting SHIP1 which is a key regulator of a cellular signaling pathway in immune cells. Aquinox Pharmaceuticals (USA) Inc. was incorporated on May&#xA0;31, 2007 in the State of Delaware, United States. On January&#xA0;27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (&#x201C;Aquinox USA&#x201D;). Aquinox Pharmaceuticals Inc. (&#x201C;AQXP Canada&#x201D;), formerly 6175813&#xA0;Canada&#xA0;Inc., was incorporated under the Canada Business Corporations Act on December&#xA0;26, 2003 and operates in Vancouver, British Columbia, Canada.</p> </div>
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3148481 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3802168
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.05
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.28
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3148481 shares
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4021937
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
641522 shares
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.052083 pure
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(b) Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates are the valuation of intangible assets, valuation of stock options and warrants, amortization and depreciation, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> </div>
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2609844
CY2014Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
2600000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2835
CY2014Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
38580
CY2014Q1 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
9844
CY2014Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
913929
CY2014Q1 us-gaap Interest Paid
InterestPaid
31719
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-106501
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1613340
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-4227678
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4463
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-734537
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-192063
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
453705
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4227678
CY2014Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
4810943
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4227678
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
734824
CY2014Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45718566
CY2014Q1 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
-491
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
19550
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137654
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
41911935
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4463
CY2014Q1 us-gaap Interest Expense
InterestExpense
453808
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
53130000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1879514
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18238
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
319635
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2614338
CY2014Q1 aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
1884233
CY2014Q1 aqxp Unrecognized Compensation Expense Weighted Average Period
UnrecognizedCompensationExpenseWeightedAveragePeriod
P1Y5M19D
CY2014Q1 aqxp Incremental Common Shares Attributable To Common Stock Warrants
IncrementalCommonSharesAttributableToCommonStockWarrants
shares
CY2014Q1 aqxp Incremental Common Shares Attributable To Stock Options
IncrementalCommonSharesAttributableToStockOptions
shares
CY2014Q1 aqxp Description Of Percentage Of Realization Of Tax Benefit Upon Settlement
DescriptionOfPercentageOfRealizationOfTaxBenefitUponSettlement
A measurement attribute that measures a given tax position as the largest amount of tax benefits that are more than 50% likely of being realized upon ultimate settlement.
CY2014Q1 aqxp Amortization Of Discount On Preferred Stock
AmortizationOfDiscountOnPreferredStock
1884233
CY2014Q1 aqxp Common Stock Reserved For Issuance Description
CommonStockReservedForIssuanceDescription
Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
CY2014Q1 aqxp Percentage Of Recognition Of Tax Benefit Upon Settlement
PercentageOfRecognitionOfTaxBenefitUponSettlement
0.50 pure
CY2014Q1 aqxp Number Of Years Shares Reserved For Issuance Will Increase
NumberOfYearsSharesReservedForIssuanceWillIncrease
P10Y
CY2014Q1 aqxp Stock Based Compensation Increase In Common Stock Issuance Percentage
StockBasedCompensationIncreaseInCommonStockIssuancePercentage
0.04 pure
CY2014Q1 aqxp Temporary Equity Accretion To Redemption Value Liquidation Preference
TemporaryEquityAccretionToRedemptionValueLiquidationPreference
1132893
CY2014Q1 aqxp Accretion Of Warrant Discount
AccretionOfWarrantDiscount
213511
CY2014Q1 aqxp Extinguishment Of Discount On Temporary Equity
ExtinguishmentOfDiscountOnTemporaryEquity
800206
CY2014Q1 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
100291
CY2014Q1 aqxp Share Issuance Expenditures Incurred But Not Yet Paid
ShareIssuanceExpendituresIncurredButNotYetPaid
390345
CY2014Q1 aqxp Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock
ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock
439227
CY2014Q1 aqxp Repayment Fee And Penalty
RepaymentFeeAndPenalty
100000
CY2014Q1 aqxp Reversal Of Income Tax Payable On Preferred Stock
ReversalOfIncomeTaxPayableOnPreferredStock
1897702

Files In Submission

Name View Source Status
0001193125-14-195836-index-headers.html Edgar Link pending
0001193125-14-195836-index.html Edgar Link pending
0001193125-14-195836.txt Edgar Link pending
0001193125-14-195836-xbrl.zip Edgar Link pending
aqxp-20140331.xml Edgar Link completed
aqxp-20140331.xsd Edgar Link pending
aqxp-20140331_cal.xml Edgar Link unprocessable
aqxp-20140331_def.xml Edgar Link unprocessable
aqxp-20140331_lab.xml Edgar Link unprocessable
aqxp-20140331_pre.xml Edgar Link unprocessable
d704250d10q.htm Edgar Link pending
d704250dex311.htm Edgar Link pending
d704250dex312.htm Edgar Link pending
d704250dex321.htm Edgar Link pending
d704250dex41.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g704250graphic-1.jpg Edgar Link pending
g704250graphic-2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending